Form 4: Cogent Biosciences Executive Acquires 525,000 Stock Options

Cole Pinnow, Chief Commercial Officer of Cogent Biosciences, acquired 525,000 stock options on May 25, 2024, according to a Form 4 filing.

Summary

• Cole Pinnow, the Chief Commercial Officer of Cogent Biosciences, acquired 525,000 stock options on May 25, 2024.
• The exercise price of these options is $8.22.
• The options vest 25% on the first anniversary of the grant date (May 25, 2024), with the remaining portion vesting in equal monthly installments over the following four years, contingent upon continued service to the Issuer.
• The options expire on May 25, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would be considered significantly positive or negative.

Future Outlook

The vesting schedule incentivizes the Reporting Person's continued service to the Issuer through May 25, 2028.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of 25% after one year followed by monthly installments is a typical vesting structure.
• The size of the grant should be compared to grants made to executives at peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders by incentivizing long-term value creation.
• The vesting schedule encourages the executive's continued service to the company.

Key Dates